PathAI
PathAI develops machine-learning tools for pathology, supporting cancer diagnosis, biomarker quantification, and clinical-trial analysis from digitised tissue slides. In May 2026 it agreed to be acquired by Roche for up to $1.05 billion ($750 million up front plus up to $300 million in milestone payments), with the transaction expected to close in the second half of 2026, subject to regulatory approval.
- Founded
- 2016
- Headquarters
- Boston, Massachusetts, US
- Founders
- Aditya Khosla, Andrew Beck
- Status
- Private; Roche acquisition agreed May 2026, pending close in H2 2026
- Total funding
- ~$490M
- Latest round
- Series C, $165M (2021)
- Key investors
- General Catalyst, D1 Capital Partners, Kaiser Permanente, General Atlantic
- Employees
- ~270
- Category
- Medical imaging AI
- Products
- AISight digital pathology, biomarker and clinical-trial algorithms
- Website
- www.pathai.com
Covered in: Artificial Intelligence in Healthcare
Sources
Profile compiled from the public sources listed above. Funding, valuation, and employee figures are point-in-time and may be out of date.